One MedImmune Way
About MedImmune, LLC
MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands. UK facilities include vaccine manufacturing operations in Speke and antibody discovery and research laboratories in Cambridge.
With two marketed products and an advancing pipeline of promising candidates in the areas of infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience, MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees.
333 articles with MedImmune, LLC
Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell Leukemia Presented at the 2018 ASCO Meeting
AstraZeneca and MedImmune, its global biologics research and development arm presented results from the Phase III (‘1053’) clinical trial (Abstract #7004) that evaluated moxetumomab pasudotox in 80 patients with relapsed or refractory hairy cell leukemia (HCL) who had received at least two prior lines of therapy.
AstraZeneca’s add-on asthma treatment Fasenra has failed a second Phase III trial this month.
IMFINZI® (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer
IMFINZI met the second primary endpoint of overall survival which was both statistically significant and clinically meaningful at a planned interim analysis
AstraZeneca and its research-and-development unit MedImmune, announced positive overall survival (OS) data for its Phase III PACIFIC trial of Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC).
Brii Biosciences Launches with $260 Million, a Partnership with Vir Biotech, and Other Relationsh...
5/24/2018Brii Biosciences is launching to accelerate the development and delivery of breakthrough drugs in China with $260 million in financial backing.
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
AstraZeneca Heads to 2018 ASCO Annual Meeting with Its Diversified Oncology Portfolio and Next-Generation Pipeline
91 accepted abstracts at ASCO, including LYNPARZA® (olaparib) in prostate cancer and moxetumomab pasudotox in hairy cell leukemia
AstraZeneca and its biologics research-and-development arm, MedImmune, indicated that its Fasenra (benralizumab) did not meet its primary endpoint in patients with moderate to very severe COPD.
Corvidia Therapeutics, headquartered in Waltham, Massachusetts, closed on a Series B funding round worth $60 million.
Sanofi announced that Elias Zerhouni, head of Global Research and Development, is retiring on June 30. The company has appointed John Reed to replace him as of July 1.
Compugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products
Compugen will receive $10 million upfront, and is eligible for milestone payments and royalties on any products developed under the license
Israel-based drug maker Compugen Ltd. and pharma giant AstraZeneca have teamed up to develop bi-specific and multi-specific immuno-oncology antibody products.
Viela Bio was spun out of AstraZeneca’s MedImmune with a Series A financing of up to $250 million.
Viela Bio Spins Out of MedImmune; Launches with Up to $250 Million Series A Financing from Investor Consortium Led by Boyu Capital, 6 Dimensions Capital, and Hillhouse Capital
Viela Bio team will focus on developing medicines for severe autoimmune diseases by targeting critical pathways that are the root cause of disease
2/17/2018IMFINZI is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer.
Innate will sponsor the study with costs equally shared by both parties.
Ticagrelor is unique among P2Y12 antagonist antiplatelet agents due to its ability to reversibly bind to the receptor, whereas other P2Y12 antagonists bind permanently.
Jane Osbourn, VP of R&D for Biosuperiors at MedImmune shares some key career tips for life science employees.
AstraZeneca Shares Scientific Updates From Its Extensive Cardiovascular, Renal and Metabolic Diseases (CVMD) Portfolio at AHA 2017
AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific focus on cardiovascular, renal and metabolic diseases (CVMD) with 28 presentations, including two late-breaking trials, at the American Heart Association (AHA) Scientific Sessions, November 11-15, 2017 in Anaheim, California.
Astra and its MedImmune division announced that two Phase III clinical trials of tralokinumab for severe, uncontrolled asthma failed to meet their primary endpoints.